编者按:Sylvia Bellucci , Hupital Robert Debré, Paris, France,致力于血小板减少症分子基础的研究。在EHA现场《肿瘤瞭望》记者就血小板减少症研究领域的进展对Sylvia Bellucci教授进行专访。
Oncology Frontier : Congratulations Professor Bellucci on the wonderful speech you just made.
肿瘤瞭望:贝鲁奇教授祝贺您做的精彩演讲。
Professor Bellucci : Thank you, thank you.
贝鲁奇教授:谢谢,谢谢。
Oncology Frontier : Could you please summarize your points so that we can share it with our Chinese readers?
肿瘤瞭望:请您与我们中国的读者分享您总结的观点.
Professor Bellucci : Yes this session was dedicated to inherited thrombocytopenias and also acquired thrombocytopenias. For acquired thrombocytopenias and particularly immune thrombocytopenias we have now a new molecule, which is active in increasing the platelet count and decreasing the hemorrhages. For inherited thrombocytopenias we have some very new information concerning genetic abnormalities in a special and very rare inherited thrombocytopenia, which is called Grey platelet syndrome. This session was very interesting.
贝鲁奇教授:好的,本次会议的部分致力于讨论遗传性血小板减少症及获得性血小板减少症。对于获得性血小板减少症,尤其是免疫血小板减少症,我们现在发现了一个新的分子,它的活性可增加血小板计数和减少出血。对于遗传性血小板减少,我们有一些非常新的资料,一些特殊的和非常罕见的遗传性血小板减少症会有遗传异常,这是所谓的灰色血小板综合征。本次会议是非常有趣的方面。